Our startup company has entered into a joint development agreement with a large enterprise. The large enterprise will make milestone payments to cover part of our R&D expenditures. However, the R&D costs related to this joint development project have not been accounted for separately but are mixed with other development activities. How should we recommend accounting treatment for this project? Historically, we have recognized milestone payments as revenue without matching corresponding cost of sales. I am wondering whether this treatment is appropriate.

Core issue: Determining the nature of milestone payments

First, it is necessary to clarify the economic substance of the milestone payments—whether they constitute compensation for R&D costs (i.e., cost sharing or subsidies) or purchase consideration for specific deliverables. This directly affects the timing and method of revenue recognition.

If the agreement stipulates that payments are linked to the progress of R&D activities and does not require the delivery of independently usable outcomes, it is more likely that the payments represent compensation for R&D investment rather than sales of goods or services to a customer. In such a case, recognizing the payments directly as revenue may overstate the enterprise's operating performance because there is no corresponding cost matching.

Potential risks of historical treatment

Your company has previously recognized milestone payments in full as revenue without recognizing any costs, which may lead to inflated gross margins and distort the reflection of the true economic results of R&D activities in the financial statements. If the payments are essentially compensation for R&D costs, the appropriate treatment would be to offset R&D expenses or recognize deferred income and release it as related costs are incurred.

Suggested accounting treatment framework

We recommend taking the following steps:

  • Reassess the terms of the agreement: Carefully review the joint development agreement to clarify the payment conditions, ownership of intellectual property, the use of R&D outcomes, and risk-bearing, in order to determine the nature of the payments.
  • Establish a cost accumulation mechanism: Even if costs are currently mixed, make every effort to separate the direct costs related to this project (such as labor, materials, and outsourcing fees) from other activities, which can be achieved by setting up an independent cost center or project code.
  • Select an accounting policy: If it is determined to be cost compensation, milestone payments should offset R&D expenses (presented on a net basis) or be recognized as contract liabilities and released as costs are incurred; if it is determined to be a customer contract, revenue should be recognized in accordance with revenue standards, with corresponding costs recognized simultaneously.
  • Disclosure and consistency: Regardless of the method chosen, the accounting policies and the basis for judgment should be fully disclosed in the notes to the financial statements, and consistency should be maintained across periods.

Considerations on whether the historical treatment was correct

Based on the information you provided, the historical treatment is likely inappropriate because the lack of cost matching leads to inflated profits. However, the final conclusion needs to be based on the specific terms of the agreement and the facts. It is recommended to consult professional accountants or auditors to obtain authoritative advice tailored to your company's situation.

Important note: This answer is general information only and does not constitute formal accounting or legal advice. Specific treatment should follow applicable accounting standards (such as IFRS or US GAAP) and local regulatory requirements.